IVD Antibody Development Services for G-CSF Marker

Creative Biolabs is a world-leading service provider of application-specific antibody development. Here, we introduce our in vitro diagnostic (IVD) antibody development and immunoassay development services targeting the granulocyte colony stimulating factor (G-CSF) marker. We are confident that our commitment to science and research will enable us to offer you the best products and services.

Granulocyte Colony Stimulating Factor (G-CSF)

Granulocyte colony-stimulating factor (G-CSF) is a cytokine that can stimulate the production of neutrophils and regulate promotes neutrophil proliferation infections and maturation. It is reported that G-CSF can bind to a single high-affinity 140-kDa receptor that is expressed early in neutrophil development to regulate the production and mature of neutrophil and the number of the mature neutrophils is increasing with the rise of G-CSF and its receptor levels. But G-CSF has almost no effects on monocytes, eosinophils, or basophils. Additionally, G-CSF has been shown that it mobilizes CD34⁺ endothelial progenitor cells (EPC) derived from bone marrow to mediate vasculogenesis into the peripheral blood.

Fig.1 Cells targeted by hematopoietic growth factor therapy.^{1, 3}

The Role of G-CSF in Sepsis

Generally speaking, patients with sepsis are more prone to die in a condition of sepsis-induced immunosuppression, contained decreased monocytic phagocytotic activity, a disorder in monocytic cytokine expression, reduced monocytic antigen presentation, lymphocytic dysfunction and the loss of circulating T-and B-lymphocytes induced by apoptosis. G-CSF has been shown to stimulate the production and mature of neutrophils to against infection. During infection, serum levels of G-CSF are elevated, both in patient with neutropenia and those without. So G-CSF can be considered as a diagnostic marker to monitor the progress of sepsis and therapeutic effect. In addition, G-CSF therapy in patients with sepsis-associated immunosuppression is allowed.

Fig.2 The complex pathogenesis of sepsis.^{2, 3}

IVD Antibody Development Services for G-CSF Marker

In recent years, IVD technologies are undergoing rapid development. IVD antibodies have been extensively used for the diagnosis of numerous diseases, conditions, or infections. Numerous candidate biomarkers were introduced as specific biomarkers for discrimination of indolent and advanced disease. As a pioneer company in the IVD market, Creative Biolabs has provided a variety of IVD antibody development services for our global customers in the most high-quality and cost-effective way.

If you are interested in the services we provide, please feel free to contact us and get a quote.

References

1. Chousterman, Benjamin G., and Marine Arnaud. "Is there a role for hematopoietic growth factors during sepsis?" Frontiers in immunology 9 (2018): 1015.
2. Huang, Min, Shaoli Cai, and Jingqian Su. "The pathogenesis of sepsis and potential therapeutic targets." International journal of molecular sciences 20.21 (2019): 5376.
3. Under Open Access license CC BY 4.0, without modification.

For Research Use Only.